PhRMA, EC unhappy with Indian patent examination draft
This article was originally published in Scrip
Executive Summary
Big pharma believes that India's draft Guidelines for Examination of Patent Applications in the Field of Pharmaceuticals uses language that generally "disparages" drug patents and that the implied scope of these guidelines exceeds that of the controversial Section 3d of India's Patent Act.